Apimeds Pharmaceuticals US, Inc. (APUS) vs China SXT Pharmaceuticals, Inc. (SXTC)

Apimeds Pharmaceuticals US, Inc. and China SXT Pharmaceuticals, Inc. are both Drug Manufacturers Specialty & Generic companies. Apimeds Pharmaceuticals US, Inc. is the larger, with a market value of $7.6M against $3.5M — 2.2× the size. Apimeds Pharmaceuticals US, Inc. has the higher net margin (0.00% vs −255.2%) and the lower return on invested capital (−16.0% vs 0.00%). Across the 10 metrics below, China SXT Pharmaceuticals, Inc. leads on 7 and Apimeds Pharmaceuticals US, Inc. on 3.

Valuation

Metric APUS SXTC Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S n/m n/m 2.25
P/B 0.12 n/m 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m 2.66 12.29
EV/Sales n/m (5.94) 2.56
Earnings yield (504.41%) (4,331.13%) (2.99%)
Free cash flow yield (107.35%) 0.00% 0.00%

Profitability

Metric APUS SXTC Drug Manufacturers Specialty & Generic median
Gross margin — 36.69% 53.94%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% (255.16%) 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (100.13%) 0.00% (0.40%)
Return on assets (84.20%) 0.00% (3.32%)
Return on invested capital (15.96%) 0.00% 0.00%

Growth

Metric APUS SXTC Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — (53.98%) 10.01%
EPS growth (last fiscal year) (205.56%) 97.36% —
Revenue growth, 5-year CAGR — (24.94%) 6.74%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric APUS SXTC Drug Manufacturers Specialty & Generic median
Debt to equity 0.08 0.03 0.05
Current ratio 0.51 7.94 2.31
Net debt to EBITDA 0.38 3.86 0.85

Dividend

Metric APUS SXTC Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio — 0.00 0.00

Size

Metric APUS SXTC Drug Manufacturers Specialty & Generic median
Market cap 7.59m 3.49m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack